Christian Winther Eskelund

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Christian Winther Eskelund, Christina Dahl, Jakob Werner Hansen et al. · Blood · 2017 · 396 citations · Full text

Medicine, Hematology, Oncology +14

15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (<scp>MCL</scp>2): prolonged remissions without survival plateau

Christian Winther Eskelund, Arne Kolstad, Mats Jerkeman et al. · British Journal of Haematology · 2016 · 215 citations · Full text

Medicine, Oncology, Cell Therapy +12

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

Mats Jerkeman, Christian Winther Eskelund, Martin Hutchings et al. · The Lancet Haematology · 2018 · 154 citations

Medicine, Oncology, Pharmacotherapy +12

<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

Simone Ferrero, Davide Rossi, Andrea Rinaldi et al. · Haematologica · 2019 · 135 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

Arne Kolstad, Lone Bredo Pedersen, Christian Winther Eskelund et al. · Biology of Blood and Marrow Transplantation · 2016 · 64 citations · Full text

Medicine, Hematology, Oncology +17